Literature DB >> 6700436

A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease.

W D Sullivan, D J Hurst, C E Harmon, J H Esther, G A Agia, J D Maltby, S B Lillard, C N Held, J F Wolfe, E V Sunderrajan.   

Abstract

Pulmonary involvement in mixed connective tissue disease (MCTD) is common, frequently severe, and is often clinically inapparent and variably responsive to corticosteroid/cyclophosphamide treatment. Serial pulmonary evaluation of patients with MCTD is important, since deterioration, as in the diffusing capacity over time, may alert the physician to the need for more invasive evaluation. Patients with a greater degree of overlap in rheumatological symptoms with an element of systemic sclerosis (PSS) may later develop severe disease. Nailfold capillary microscopy also may help in determining which patients will develop severe pulmonary involvement. Significant pulmonary hypertension occurs and cannot be accurately predicted on the basis of history, physical examination, pulmonary function tests, gallium scanning, or exercise testing. The characteristic pathological finding was intimal proliferation with medial muscular hypertrophy in the pulmonary arterioles. In contrast, pulmonary interstitial abnormalities were minimal, suggesting the proliferative vascular lesions are more closely associated with pulmonary hypertension in MCTD. Some patients develop rapidly progressive disease with varying response to corticosteroid and cytotoxic agents. More commonly, however, MCTD patients with long-term disabling disease, including pulmonary dysfunction, have had significant improvement with steroid and/or cyclophosphamide treatment, and clinical remission has occurred in 38% of the patients in this series.

Entities:  

Mesh:

Year:  1984        PMID: 6700436     DOI: 10.1097/00005792-198403000-00003

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  37 in total

Review 1.  Imaging of the pulmonary manifestations of systemic disease.

Authors:  A G Rockall; D Rickards; P J Shaw
Journal:  Postgrad Med J       Date:  2001-10       Impact factor: 2.401

Review 2.  Treatment of pulmonary hypertension secondary to connective tissue diseases.

Authors:  O Sanchez; M Humbert; O Sitbon; G Simonneau
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

3.  Recovery from pulmonary hypertension in an adolescent with mixed connective tissue disease.

Authors:  D M Friedman; H J Mitnick; D Danilowicz
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

Review 4.  'Overlap' syndromes.

Authors:  R Cervera; M A Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

5.  Lymphadenopathy in a 20-year-old woman with mixed connective tissue disease.

Authors:  J M Zijlmans; P M Kluin; L J Schultze Kool; R Bieger
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

6.  Diastolic function of the heart in mixed connective tissue disease.

Authors:  Judit Végh; Ida Hegedus; Gyula Szegedi; Margit Zeher; Edit Bodolay
Journal:  Clin Rheumatol       Date:  2006-07-25       Impact factor: 2.980

Review 7.  Mixed connective tissue disease, overlap syndromes, and eosinophilic fasciitis.

Authors:  P J Maddison
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

8.  The treatment of primary pulmonary hypertension.

Authors:  N G Uren; C M Oakley
Journal:  Br Heart J       Date:  1991-08

9.  Cellular regulation of anti-nRNP antibody synthesis is different from that of anti-DNA antibody synthesis in patients with systemic lupus erythematosus.

Authors:  O Hosono; T Takeuchi; J Koide; M Takano; T Abe
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

10.  Pulmonary hypertension associated with primary biliary cirrhosis in the absence of portal hypertension: a case report.

Authors:  E M Yoshida; S R Erb; D N Ostrow; D R Ricci; C H Scudamore; G Fradet
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.